The proposal, unveiled by the Senate Appropriations Committee, marks a significant shift in federal policy. While the House of Representatives previously advanced a spending version lacking these protections, the inclusion of hemp provisions in the Senate draft signals a potential legislative victory. The U.S. Hemp Roundtable described the development as a critical win, noting that the measure would exempt most naturally derived hemp products while maintaining restrictions on certain synthetic cannabinoids that cannot be produced by the Cannabis sativa L. plant.

For Charlotte-based cbdMD, the legislation represents an opportunity to stabilize the market. CEO T. Ronan Kennedy characterized the extension as a bridge rather than a final solution. He emphasized that embedding these protections directly into a must-pass spending bill provides the industry with a platform to advocate for permanent, transparent regulatory standards. The company, which maintains a portfolio including Bluebird Botanicals and Paw CBD, expects its core offerings to remain protected under the current language. Final enactment remains contingent on reconciliation between the House and Senate and a presidential signature before the December deadline.